1. Home
  2. KRRO vs NERV Comparison

KRRO vs NERV Comparison

Compare KRRO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

SELL

Current Price

$10.02

Market Cap

142.0M

Sector

Health Care

ML Signal

SELL

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

SELL

Current Price

$3.29

Market Cap

166.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
KRRO
NERV
Founded
2014
2007
Country
United States
United States
Employees
57
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
142.0M
166.4M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
KRRO
NERV
Price
$10.02
$3.29
Analyst Decision
Strong Buy
Buy
Analyst Count
11
3
Target Price
★ $20.20
$10.33
AVG Volume (30 Days)
★ 195.1K
119.2K
Earning Date
11-11-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
$6,392,000.00
★ $41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
$240.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 181.46
N/A
52 Week Low
$5.20
$2.14
52 Week High
$55.89
$12.46

Technical Indicators

Market Signals
Indicator
KRRO
NERV
Relative Strength Index (RSI) 38.09 33.37
Support Level $9.76 N/A
Resistance Level $14.50 $4.73
Average True Range (ATR) 0.96 0.27
MACD -0.14 -0.03
Stochastic Oscillator 12.80 14.77

Price Performance

Historical Comparison
KRRO
NERV

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: